Your session is about to expire
← Back to Search
Norepinephrine-Dopamine Reuptake Inhibitor
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Phase 3
Waitlist Available
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 59 days
Awards & highlights
Pivotal Trial
Summary
This study evaluates the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder (ADHD). Participants will either receive a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.
Eligible Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 59 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 59 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)
Secondary study objectives
Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S)
Other study objectives
ADHD Impact Module - Adult (AIM-A)
Adult ADHD Investigator Symptom Rating Scale (AISRS)
Adult ADHD Self Report Scale (ASRS)
+1 moreAwards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Single-blind Run-in Period: PlaceboExperimental Treatment1 Intervention
Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
Group II: Double-blind Treatment Period: Centanafadine SR 400 mgExperimental Treatment1 Intervention
Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
Group III: Double-blind Treatment Period: Centanafadine SR 200 mgExperimental Treatment1 Intervention
Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
Group IV: Double-blind Treatment Period: PlaceboPlacebo Group1 Intervention
Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Centanafadine SR
2019
Completed Phase 3
~1860
Find a Location
Who is running the clinical trial?
Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
266 Previous Clinical Trials
168,508 Total Patients Enrolled
10 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
3,875 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)